Xuemei Wang, M.S.

Associate Director, Quantitative Research


  • M.S. in Biostatistics, University of Iowa, Iowa City, Iowa, 1999
  • B.S. in Biochemistry, Nankai University, Tianjin, Peoples Republic of China, 1996

Areas of Interest

  • Clinical trial design and analysis
  • Survival analysis
  • Statistical computing


Peer-reviewed articles


Lin P, Dickason TJ, Fayad LE, Lennon PA, Hu P, Garcia M, Routbort MJ, Miranda R, Wang X, Qiao W, Medeiros LJ. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer 2012; [Advance publication online: DOI: 10.1002/cncr.26433].

Atiq M, Bhutani MS, Bektas M, Lee JE, Gong Y, Tamm EP, Shah CP, Ross WA, Yao J,  Raju GS, Wang X, Lee JH. EUS-FNA for pancreatic neuroendocrine tumors: A tertiary cancer center experience. Digestive Diseases and Sciences 2012; [Advance publication online: DOI 10.1007/s10620-011-1912-7].

Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer  2012; [Advance publication online: DOI: 10.1002/cncr.2658]

Katz MH, Wang H, Balachandran A, Bhosale P, Crane CH, Wang X, Pisters PW, Lee JE, Vauthey JN, Abdalla EK, Wolff R, Abbruzzese J, Varadhachary G, Chopin-Laly X, Charnsangavej C, Fleming JB. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. Journal of Gastrointestinal Surgery 2012; [Advance publication online: DOI: 10.1007/s11605-011-1748-7].


Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A, Wang X, Lodhi A, Krishnamurthy S, Hortobagyi GN, Cristofanilli M, Lucci A, Woodward WA. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype. European Journal of Cancer 2011: 47(10):1527-1536.

Alatrash G, de Lima M, Hamerschlak N,  Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, SaIiba RM, Champlin RE,  Andersson BS. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.  Biology of Blood and Marrow Transplantation 2011; 17(10):1490–1496.

Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, Aung F, Rondon G, Molldrem JJ, Korbling M, Shpall EJ, de Lima M, Champlin RE, Fernandez-Vina M. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation.  Blood 2011; 118(22):5957-5964.

Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL,  Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 2011; 117(21):4939–4947.

Badoux X, Keating M, Wang X, O'Brien S, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Weirda W. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood 2011; 118(8):2085-2093.

Parikh SA, Keating MJ, O’Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab for high-risk chronic lymphocytic leukemia. Blood 2011; 118(8):2062–2068.

Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JB, Cristofanilli M. Characterization of metastatic breast cancer patients with non-detectable circulating tumor cells. International Journal of Cancer 2011;129(2):417-423.

Wierda W, O’Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Schlette E, Abruzzo L, Kantarjian H, Keating M. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology 2011; 29(31):4088-4095.

Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biology of Blood and Marrow Transplantation 2011; 17(6):893–900.

Sun J, Konoplev SN, Wang X, Cui W, Chen SS, Medeiros LJ, Lin P. De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification. Modern Pathology 2011; 24(3):384-389.

Kebriaei P, Madden T, Kazerooni R, Wang X, Thall P, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones R, Andersson BS. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biology of Blood and Marrow Transplantation 2011; 17(3):412-420.

Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitor. Molecular Cancer Therapeutics 2011; 10(3):558-565.

Badoux XC, Keating MJ, Wang X, O’Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011; 117(11):3016-3024.

Janku F, Tsimberidou AM, Wang X, Hong DS, Gong J, Naing A, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinical trial. Oncologist 2011; 16(3):327-335.


Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clinical Cancer Research. 2010;16:4031-4037.

Konoplev SN, Fritsche HA, O'Brien S, Wierda WG, Keating MJ, Gornet TG, St Romain S, Wang X, Inamdar K, Johnson MR, Medeiros LJ, Bueso-Ramos CE. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. American Journal of Clinical Pathology. 2010;134:472-477.

Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010;78:316-322.

Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer. 2010;116:4487-4494.

Sexton WJ, Spiess PE, Pisters LL, Carpenter S, Madsen LT, Zagone R, Wang X, Troncoso P. Are there differences in zonal distribution and tumor volume of prostate cancer in patients with a positive family history? International Brazilian Journal of Urology. 2010;36:571-582.

Shapiro JF, Chase JL, Wolff RA, Lambert LA, Mansfield PF, Overman MJ, Ohinata A, Liu J, Wang X, Eng C. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010;116:316-322.

Vadhan-Raj S, Zhou X, Sizer K, Lal L, Wang X, Roquemore J, Shi W, Benjamin RS, Lichtiger B. Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions. Oncologist. 2010;15:1359-1369.

Efstathiou E, Abrahams NA, Wang X, Pettaway CA, Pisters LL, Logothetis CJ, Troncoso P. Morphologic characterization of preoperatively treated prostate cancer: toward a classification of prostate cancer in the preoperative surgical model. European Urology. 2010;57:1030–1038.

Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, Wojcik SE, Ferdin J, Kunej T, Xiao L, Manoukian S, Secreto G, Ravagnani F, Wang X, Radice P, Croce CM, Davuluri RV, Calin GA. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Research. 2010;70:2789–2798.

Shapiro JF, Chase JL, FASHP, Wolff RA, Lambert LA, Mansfield PF, Ohinata A, Liu J, Wang X, Eng C. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single institution experience. Cancer. 2010;116:316–322.

Ajani JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid A. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Digestive Diseases and Sciences. 2010;55:1098-1105.

Anaya DA, Lahat G, Wang X, Xiao L, Tuvin D, Pisters PW, Lev DC, Pollock RE. Postoperative nomogram for survival in patients with retroperitoneal sarcoma treated with curative intent. Annals of Oncology. 2010;21:379–402.

Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). British Journal of Haematology. 2010;148:386-393.

Rosen DG, Zhang Z, Chang B, Wang X, Lin E, Liu J. Low membranous expression of β-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary. Modern Pathology. 2010;23:113–122.


Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H, Wang X, Ajani JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009;115:5184-5192.

Wrede B, Hasselblatt M, Peters O, Thall PF, Kutluk T, Moghrabi A, Mahajan A, Rutkowski S, Diez B, Wang X, Pietsch T, Kortmann RD, Paulus W, Jeibmann A, Wolff JEA. Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study. Journal of Neuro-Oncology. 2009;95:383–392.

Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, Ravandi F, Kantarjian H, Champlin R, Estey E. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biology of Blood and Marrow Transplantation. 2009;15:1431–1438.

Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, Wang X, Thall PF, Champlin RE, Fernandez-Vina M. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem cell transplantation. Transplantation. 2009;88:1019–1024.

Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, Jones P, Yang A, Issa JPJ. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics. 2009;4:176–184.

Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Modern Pathology. 2009;22:817–823.

Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 2009;27:4076–4081.

Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. Journal of the National Cancer Institute. 2009;101:306–320.

Mandelin J, Lin ECK, Hu DD, Knowles SK, Do KA, Wang X, Sage EH, Smith JW, Arap W, Pasqualini R. Extracellular and intracellular mechanisms that mediate the metastatic activity of exogenous osteopontin. Cancer. 2009;115:1753–1764.

Anaya DA, Lahat G, Wang X, Xiao L, Tuvin D, Pisters PW, Lev DC, Pollock RE. Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm. Annals of Surgical Oncology. 2009;16:667–675.

Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. Journal of Clinical Oncology. 2009;27:1637-1643.

Lahat G, Lazar A, Wang X, Wang W, Zhu Q, Hunt KK, Pollock RE, Lev D. Increased vascular endothelial growth factor-C expression is insufficient to induce lymphatic metastasis in human soft-tissue sarcomas. Clinical Cancer Research. 2009;15:2637-2646.

Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM,  Logothetis CJ, Kim J. Selenium and vitamin E: cell type– and intervention-specific tissue effects in prostate cancer. Journal of the National Cancer Institute. 2009;101:306-320.

Javeri H, Xiao L, Rohren E, Komaki R, Hofstetter W, Lee JH, Maru D, Bhutani MS, Swisher SG, Wang X, Ajani JA. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer. 2009;115:624–630.


Tannir NM, Ng C, Thall PF, Wang X, Wooten L, Patterson L, Mathew P, Pagliaro L, Siefker-Radtke A, Jonasch E. A phase II trial of gemcitabine plus capecitabine in metastatic renal cancer previously treated with immunotherapy and targeted agents. The Journal of Urology. 2008;180:867–872.

Borthakur G, Kantarjian H, Wang X, Plunkett WK Jr, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008;113:3181-3318.

Inamdar KV, O’Brien S, Sen S, Keating M, Nguyen MH, Wang X, Fernandez M, Medeiros LJ, Bueso-Ramos CE. Aurora-A kinase nuclear expression in chronic lymphocytic leukemia. Modern Pathology. 2008;21:1428–1435.

Pettaway CA, Song R, Wang X, Sanchez-Ortiz R, Spiess PE, Strom S, Troncoso P. The ratio of matrix metalloproteinase to E-cadherin expression: a pilot study to assess mRNA and protein expression among African American prostate cancer patients. The Prostate. 2008;68:1467-1476.

Jin Z, Lahat G, Korchin B, Nguyen T, Zhu Q, Wang X, Lazar AJ, Trent J, Pollock RE, Lev D, Midkine enhances soft tissue sarcoma growth; a possible novel therapeutic target. Clinical Cancer Research. 2008;14:5033-5042.


Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer. 2006;106(2):337-345.

Spiess PE, Kassouf W, Brown G, Highshaw R, Wang X, Kamat AM, Czerniak B, Dinney CP, Grossman HB.  Immediate versus staged urethrectomy in patients at high-risk of urethral recurrence: Is there a benefit to either approach? Urology. 2006;67(3):466-471.

Soliman AS, Wang X, Stanley JD, El-Ghawalby N, Bondy ML, Ezzat F, Soultan A, Abdel-Wahab M, Fathy O, Ebidi G, Abdel-Karim N, Do KA, Levin B, Hamilton SR, Abbruzzese JL. Geographical Clustering of Pancreatic Cancers in the Northeast Nile Delta Region of Egypt. Archives of Environmental Contamination and Toxicology. 2006;51(1):142-148.

Steinert DM, Trent JC, Oyarzo M, Wang X, Thall PF, Medeiros LJ, Raymond K, Benjamin RS. Expression of Bcl-2 in Gastrointestinal Stromal Tumors:  Correlation of Progression-Free Survival with Imatinib Mesylate Therapy in 81 Patients. Cancer. 2006;106(7):1617-1623.

Rosser CJ, Kamat AM, Wang X, Do KA, Naya Y, Hoover DC, Troncoso P, Sanches-Ortiz RF, Pisters LL.  Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology. 2006;67(4):769-773.

Merzianu M, Jiang L, Lin P, Wang X, Weber DM, Vadhan-Raj S, Nguyen MH, Medeiros LJ, Bueso-Ramos CE. Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-κB activation. Modern Pathology. 2006;19(7):891-898.

Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ. Targeting Platelet-Derived Growth Factor Receptor on Endothelial Cells of Multidrug-Resistant Prostate Cancer. Journal of the National Cancer Institute. 2006;98(11):783-793.

Spiess PE, Lee AK, Leibovici D, Wang X, Do KA, Pisters LL. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer. 2006;107(2):275-280.

Busby JE, Kim SJ, Yazici S, Nakamura T, Kim JS, He J, Maya M, Wang X, Do KA, Fan D, Fidler IJ. Therapy of Multidrug Resistant Human Prostate Tumors in the Prostate of Nude Mice by Simultaneous Targeting of the EGF-R and VEGF-R on Tumor-associated Endothelial Cells. The Prostate. 2006;66(16):1788-1798.

Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon alfa 2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer. 2006;107(9):2254-2261.


Rosser CJ, Kamat AM, Wang X, Do KA, Sanchez-Ortiz RF, Kuban DA, Lee AK, Cheung R, Chichakli R, Pisters LL. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer?  Urology. 2005;66(2):327-331.

Wong R, Shahjahan M, Wang X, Thall PF, de Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.  Biology of Blood and Marrow Transplantation. 2005;11(2):108-114.

Leibovici D, Kamat AM, Do KA, Pettaway CA, Ng CS, Evans RB, Rodriguez-Bigas M, Skibber J, Wang X, Pisters LL. Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer. The Prostate. 2005;62(1):101-104.

Cho-Vega JH, Troncoso P, Do KA, Rago C, Wang X, Tsavachidis S, Medeiros LJ, Spurgers K, Logothetis C, McDonnell TJ. Combined laser capture microdissection and serial analysis of gene expression from human tissue samples. Modern Pathology. 2005;18(4):577-584.


Assikis VJ, Do KA, Wen S, Wang X, Cho-Vega JH, Brisbay S, Lopez R, Logothetis CJ, Troncoso P, Papandreou CN, McDonnell TJ. Clinical and Biomarker Correlates of Androgen-Independent, Locally Aggressive Prostate Cancer with Limited Metastatic Potential. Clinical Cancer Research. 2004;10(20):6770-6778.

Cormier JN, Huang X, Xing Y, Thall PF, Wang X, Benjamin RS, Pollock RE, Antonescu CR, Maki RG, Brennan MF, Pisters PWT. Cohort Analysis of Patients With Localized, High-Risk, Extremity Soft Tissue Sarcoma Treated at Two Cancer Centers: Chemotherapy-Associated Outcomes. Journal of Clinical Oncology. 2004;22(22):4567-4574.

Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang X, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors. Clinical Cancer Research. 2004;10(9):2968-2976.

Pisters L, Pettaway C, Troncoso P, McDonnell T, Stephens C, Wod C, Do KA, Brisbay S, Wang X, et al. Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer. Clinical Cancer Research. 2004,10(8):2587-2593.

Lin P, Hao S, Medeiros J, Estey E, Pierce S, Wang X, et.al. Expression of CD2 in Acute Promyelocytic Leukemia Correlates with Short Form of PML-RARa Transcripts and Poorer Prognosis. American Journal of Clinical Pathology. 2004;121(3):402-407.

Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer. Journal of Clinical Oncology. 2004;22(11):2108-2121.

de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall RJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104(3):857-864.


Frank SJ, Forster KM, Stevens CW, Cox JD, Komaki R, Liao Z, Tucker S, Wang X, Steadham RE, Brooks C, Starkschall G. Treatment planning for lung cancer: Traditional homogeneous point–dose prescription compared with heterogeneity-corrected dose–volume prescription, International Journal of Radiation Oncology, Biology, Physics. 2003;56(5):1308-1318.

Estey E, Thall P, Wang X, et al. Effect of Circulating Blasts at Time of Complete Remission on Subsequent Relapse-Free Survival Time in Newly-Diagnosed AML. Blood. 2003;102:3097-3099.

Daliani DD, Assikis V, Tu SM,  Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ. Phase II Trial of Cyclophosphamide, Vincristine and Dexamethasone in the Treatment of Androgen-Independent Prostate Cancer. Cancer. 2003;97(9):561-567.

Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, Albitar M. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101(3):2507-2513.

Soliman AS, Wang X, DiGiovanni J, Eissa S, Morad M, Vulimiri S, Mahgoub KG, Johnston DA, Do KA, Seifeldin IA et al. Serum organochlorine levels and history of lactation in Egypt. Environmental Research. 2003;92(7):110-117.

Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nature Biotechnology. 2003;21(2):57-63.


Andersson B, Couriel D, Thall P, Madden T, Wang X, et al. Busulfan Systemic Exposure Relative to Regimen-Related Toxicity and Acute Graft vs. Host Disease; Defining a Therapeutic Window for IV BuCy 2 in Chronic Myelogenous Lekemia. Biology of Blood and Marrow Transplantation. 2002;8(1):477-485.

Sample D, Wargovich M, Fischer SM, Inamdar N, Schwartz P, Wang X, Do KA, Sinicrope FA.  A Dose-finding Study of Aspirin for Chemoprevention Utilizing Rectal Mucosal Prostaglandin E2 Levels as a Biomarker. Cancer Epidemiology Biomarkers and Prevention. 2002;11(3):275-279.

Fizazi K, Do KA, Wang X, Finn L, Logothetis CJ, Amato RJ.  A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. Annals of Oncology. 2002;13(1):125-134.

Daliani D, Papandreou C, Thall P, Wang X, et al. A Pilot Study of Thalidomide in Patients with Progressive Metastatic Renal Cell Carcinoma. Cancer;2002:95(4):758-765.

Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate. Journal of Clinical Oncology. 2002;20(14):3072-3080.

Estey EH, Thall PF, Giles FJ, Wang X, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside, Blood. 2002;99(12):4343-4349.

Vauthey JN, Abdalla EK, Doherty DA, Gertsch P, Fenstermacher MJ, Loyer EM, Lerut J, Materne R, Wang X, et al. Body Surface Area and Body Weight Predict Total Liver Volume in Western Adults. Liver Transplantation. 2002;83(3):233-240.

Strom SS, Wang X, Pettaway CA, Logothetis CJ, Yamamura Y, Do KA, Babaian RJ, Troncoso P. Obesity, Weight Gain, and Risk of Biochemical Failure among Prostate Cancer Patients following Prostatectomy. Clinical Cancer Research. 2002;11(19 Pt 1):6889-6894.

Ahmad SA, Patel SR, Ballo MT, Baker TP, Yasko AW, Wang X, Feig BW, Hunt KK, Lin PP, Weber KL, Chen LL, Zagars GK, Pollock RE, Benjamin RS, Pisters PWT. Extraosseous Osteosarcoma: Response to Treatment and Long-Term Outcome. Journal of Clinical Oncology. 2002;20(2):521-527.


Do KA, Broom B, Wang X. Importance of bootstrap resampling for proportional hazards regression. Communications in Statistics: Theory and Methods. 2001;30(10):2173-2189.

Giralt S, Thall PF, Khouri I, Wang X, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97(3):631-637.

Chang D, Langstein H, Gupta A, Monte F, Do KA, Wang X, et al. Reconstruction Management of Cranial Base Defects Following Tumor Ablation. Plastic Reconstructive Surgery. 2001;107(6):1346-1355.

Esmaeli B, Wang X, et al. Patterns of Clinical Lymph Node and Distant Metastasis in Patients with Conjunctival Melanoma: Experience at a Cancer Center for Four Decades. The Journal of American Academy of Ophthalmology. 2001;108(11):2101-2105.

Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, et al. Comparison of Idarubicin + ara-C-, Fludarabine + ara-C-, and Topotecan + ara-C- Based Regimens in Treatment of Newly-Diagnosed AML, RAEB-t, or RAEB. Blood. 2001;98(13):3575-3583

Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2001;92(9):2364-2373.

Ahmad SA, Bilimoria MM, Wang X, Izzo F, Delrio P, Marra P, Baker TP, Porter GA, Ellis LM, Vauthey JN, Dhamotharan S, Curley SA. Hepatitis B or C virus serology as a prognostic factor in patients with hepatocellular carcinoma. Journal of Gastrointestinal Surgery. 2001;5(5):468-476.

Book chapters

Thall PF, Wang X. Bayesian sensitivity analyses of confounded treatment effects. In: JC Crowley and DP Pauler (eds) Handbook of Statistics in Clinical Oncology: Second Edition, Revised and Expanded, pp. 523-540, Boca Raton: Chapman & Hall/CRC Taylor & Francis Group, 2006.

Thall PF, Wang, X. Parametric likelihoods for multiple non-fatal competing risks and death, with application to cancer data. In K. Peace (ed) Design and Analysis of Clinical Trials with Time-to-Event Endpoints, pp. 371-386, Boca Raton: Chapman & Hall/CRC Taylor & Francis Group, 2009.


Updated February 1, 2012